Free Trial Information
BioCentury | Aug 27, 2019
Company News

Aug. 27 Company Quick Takes: GSK licenses Ionis HBV program; plus Adaptimmune-Noile, Purdue, Presage-BMS, Kyowa, Alexion, Viela, Kintai, OncoNano

...AbbVie Inc. (NYSE:ABBV) co-developed the drug with BMS. BMS deal third for Presage’s microdosing platform Presage Biosciences...
...Center and Research Institute Ionis Pharmaceuticals Inc. Kintai Therapeutics Inc. Kyowa Hakko Kirin Co. Ltd. Noile-Immune Biotech Inc. OncoNano Medicine Inc. Presage Biosciences Purdue...
Read More
BioCentury | May 2, 2019
Company News

May 2 Company Quick Takes: Agios, Celgene/Presage, Purdue, Amgen/Syapse

...a susceptible IDH1 mutation. Celgene, Presage partner on microdosing trials Celgene Corp. (NASDAQ:CELG) will tap Presage Biosciences...
...Terms were not disclosed. Mark Zipkin, Staff Writer Tibsovo, ivosidenib (AG-120, CS3010, IDH1 inhibitor) Agios Pharmaceuticals Inc. Amgen Inc. Celgene Corp. Presage Biosciences Purdue...
Read More
BioCentury | Jul 17, 2018
Company News

Management tracks: Silence, Apeiron

...adviser and VP of business development at The Medicines Co. (NASDAQ:MDCO). Cancer drug screening company Presage Biosciences...
Read More
BioCentury | Sep 8, 2017
Company News

Presage grants MEI rights to cancer candidate voruciclib

...Presage Biosciences , Seattle, Wash. MEI Pharma Inc. (NASDAQ:MEIP), San Diego, Calif. Business: Cancer Alicia Parker P1446A-05 Voruciclib MEI Pharma Inc. Presage Biosciences Cyclin...
Read More
BioCentury | Aug 24, 2015
Financial News

Presage Biosciences completes venture financing

Presage Biosciences , Seattle, Wash. Business: Supply/Service Date completed: 2015-08-20 Type: Venture financing Raised: Not disclosed Investor: Takeda Ventures Inc. Note: The amount raised is not disclosed. WIR Staff...
Read More
BioCentury | Mar 11, 2013
Company News

Celgene, Presage Biosciences deal

...drug combinations for solid tumors (see BioCentury, April 9, 2012). Celgene Corp. (NASDAQ:CELG), Summit, N.J. Presage Biosciences...
Read More
BioCentury | Mar 6, 2013
Company News

Presage, Celgene in cancer deal

Presage Biosciences (Seattle, Wash.) partnered with Celgene Corp. (NASDAQ:CELG) to use Presage's technology to identify new drug combinations for solid tumors indications. Presage will receive $5 million up front in research funding and an $8...
Read More
BioCentury | May 7, 2012
Tools & Techniques

Comparing combos quickly

...Millennium Pharmaceuticals Inc. is using an in vivo screening platform from Presage Biosciences Inc. to speed up...
...U.K. Fred Hutchinson Cancer Research Center , Seattle, Wash. Millennium Pharmaceuticals Inc. , Cambridge, Mass. Presage Biosciences...
Read More
BioCentury | Apr 9, 2012
Company News

Presage Biosciences, Takeda deal

...for the selection and optimization of promising drug combinations earlier in the drug development process. Presage Biosciences...
Read More
BioCentury | Apr 6, 2012
Top Story

Presage, Millennium in cancer deal

Presage Biosciences (Seattle, Wash.) partnered with the Millennium Pharmaceuticals Inc. subsidiary of Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) to use Presage's technology for preclinical identification of effective drug combinations in solid tumors. Presage will receive upfront...
Read More
Items per page:
1 - 10 of 13
BioCentury | Aug 27, 2019
Company News

Aug. 27 Company Quick Takes: GSK licenses Ionis HBV program; plus Adaptimmune-Noile, Purdue, Presage-BMS, Kyowa, Alexion, Viela, Kintai, OncoNano

...AbbVie Inc. (NYSE:ABBV) co-developed the drug with BMS. BMS deal third for Presage’s microdosing platform Presage Biosciences...
...Center and Research Institute Ionis Pharmaceuticals Inc. Kintai Therapeutics Inc. Kyowa Hakko Kirin Co. Ltd. Noile-Immune Biotech Inc. OncoNano Medicine Inc. Presage Biosciences Purdue...
Read More
BioCentury | May 2, 2019
Company News

May 2 Company Quick Takes: Agios, Celgene/Presage, Purdue, Amgen/Syapse

...a susceptible IDH1 mutation. Celgene, Presage partner on microdosing trials Celgene Corp. (NASDAQ:CELG) will tap Presage Biosciences...
...Terms were not disclosed. Mark Zipkin, Staff Writer Tibsovo, ivosidenib (AG-120, CS3010, IDH1 inhibitor) Agios Pharmaceuticals Inc. Amgen Inc. Celgene Corp. Presage Biosciences Purdue...
Read More
BioCentury | Jul 17, 2018
Company News

Management tracks: Silence, Apeiron

...adviser and VP of business development at The Medicines Co. (NASDAQ:MDCO). Cancer drug screening company Presage Biosciences...
Read More
BioCentury | Sep 8, 2017
Company News

Presage grants MEI rights to cancer candidate voruciclib

...Presage Biosciences , Seattle, Wash. MEI Pharma Inc. (NASDAQ:MEIP), San Diego, Calif. Business: Cancer Alicia Parker P1446A-05 Voruciclib MEI Pharma Inc. Presage Biosciences Cyclin...
Read More
BioCentury | Aug 24, 2015
Financial News

Presage Biosciences completes venture financing

Presage Biosciences , Seattle, Wash. Business: Supply/Service Date completed: 2015-08-20 Type: Venture financing Raised: Not disclosed Investor: Takeda Ventures Inc. Note: The amount raised is not disclosed. WIR Staff...
Read More
BioCentury | Mar 11, 2013
Company News

Celgene, Presage Biosciences deal

...drug combinations for solid tumors (see BioCentury, April 9, 2012). Celgene Corp. (NASDAQ:CELG), Summit, N.J. Presage Biosciences...
Read More
BioCentury | Mar 6, 2013
Company News

Presage, Celgene in cancer deal

Presage Biosciences (Seattle, Wash.) partnered with Celgene Corp. (NASDAQ:CELG) to use Presage's technology to identify new drug combinations for solid tumors indications. Presage will receive $5 million up front in research funding and an $8...
Read More
BioCentury | May 7, 2012
Tools & Techniques

Comparing combos quickly

...Millennium Pharmaceuticals Inc. is using an in vivo screening platform from Presage Biosciences Inc. to speed up...
...U.K. Fred Hutchinson Cancer Research Center , Seattle, Wash. Millennium Pharmaceuticals Inc. , Cambridge, Mass. Presage Biosciences...
Read More
BioCentury | Apr 9, 2012
Company News

Presage Biosciences, Takeda deal

...for the selection and optimization of promising drug combinations earlier in the drug development process. Presage Biosciences...
Read More
BioCentury | Apr 6, 2012
Top Story

Presage, Millennium in cancer deal

Presage Biosciences (Seattle, Wash.) partnered with the Millennium Pharmaceuticals Inc. subsidiary of Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) to use Presage's technology for preclinical identification of effective drug combinations in solid tumors. Presage will receive upfront...
Read More
Items per page:
1 - 10 of 13